

Final review questions covered in this guideline

No.	Review question
1	In whom should obstructive sleep apnoea/hypopnoea syndrome, obesity hypoventilation syndrome or overlap syndrome be suspected (for example, based on symptoms or coexisting conditions)?
2	What assessment scales should be used if obstructive sleep apnoea/hypopnoea syndrome, obesity hypoventilation syndrome or overlap syndrome is suspected (for example, the Epworth sleepiness scale, STOP-Bang sleep apnoea questionnaire or Berlin questionnaire)?
3	Which people with suspected obstructive sleep apnoea/hypopnoea syndrome, obesity hypoventilation syndrome or overlap syndrome should be prioritised for further assessment?
4	What are the most clinically and cost effective diagnostic strategies for obstructive sleep apnoea/hypopnea syndrome, obesity hypoventilation syndrome and overlap syndrome, including home- and hospital-based studies, and investigations such as oximetry, capnography, respiratory polygraphy and polysomnography?
5	What is the clinical and cost effectiveness of treatment of rhinitis to improve symptoms of obstructive sleep apnoea/hypopnoea syndrome obesity hypoventilation syndrome or overlap syndrome?
6	What is the clinical and cost effectiveness of upper airway surgical interventions for people with obstructive sleep apnoea/hypopnoea syndrome?
7	What is the clinical and cost effectiveness of interventions to modify sleeping position for people with obstructive sleep apnoea/hypopnoea syndrome?
8	What is the clinical and cost effectiveness of different types of oral devices for managing obstructive sleep apnoea/hypopnoea syndrome and overlap syndrome?
9	What is the comparative clinical and cost effectiveness of different types of positive airway pressure devices (for example, fixed-pressure CPAP, variable-pressure CPAP, bi-level positive airway pressure or other modes of non-invasive ventilation) for managing obstructive sleep apnoea/hypopnoea syndrome, obesity hypoventilation syndrome and overlap syndrome?
10	What is the clinical and cost-effectiveness of CPAP devices for the treatment of mild OSAHS?
11	What is the clinical and cost effectiveness of oxygen therapy for managing obstructive sleep apnoea/hypopnoea syndrome, obesity hypoventilation syndrome and overlap syndrome?
12	What is the clinical and cost effectiveness of oxygen therapy adjunctive to ventilatory support for people who do not fulfil long term oxygen therapy (LTOT) criteria for managing obstructive sleep apnoea/hypopnoea syndrome, obesity hypoventilation syndrome and overlap syndrome?
13	What is the clinical and cost effectiveness of the addition of humidification to positive airway pressure therapy for managing obstructive sleep apnoea/hypopnoea syndrome, obesity hypoventilation syndrome and overlap syndrome?
14	What support improves adherence to CPAP or other interventions?

15	How should efficacy of treatment be demonstrated (for example, variable positive pressure titration device, oximetry, capnography or polysomnography titration)?
16	What is the most clinically and cost effective strategy for monitoring obstructive sleep apnoea/hypopnoea syndrome, obesity hypoventilation syndrome and overlap syndrome (for example, based on outpatient visits, download of data from devices or telemonitoring)?
17	What is the optimum frequency of monitoring of obstructive sleep apnoea/hypopnoea syndrome, obesity hypoventilation syndrome and overlap syndrome?
18	What information and support do people and their families or carers need (for example, advice on lifestyle, driving and occupation, and their treatment)?